Advanced Medical Optics and Ophtec to work on new phakic IOL (intraocular lens):
This article was originally published in Clinica
Executive Summary
Advanced Medical Optics (AMO) and Ophtec are to collaborate on the design and regulatory approval strategy of Veriflex, a new foldable version of the Verisyse phakic intraocular lens (IOL) for which AMO holds global distribution rights. Under a similar agreement for Veriflex, AMO will be the exclusive distributor of the lens in the US, Japan and Europe. Both the Veriflex and Verisyse phakic IOLs are designed for implantation in patients whose refractive errors cannot be corrected by current refractive surgical methods such as LASIK. The Verisyse, already available in Europe, is currently awaiting the final green light from the FDA after having received approval recommendation from the ophthalmic devices panel in February this year.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.